A shorter radiation regimen can be just as safe and effective for breast cancer patients who want reconstruction surgery, a new clinical trial says.
A three-week radiation schedule worked just as well as the standard five-week treatment for women undergoing breast reconstruction post-mastectomy, researchers reported Oct. 12 in the Journal of Clinical Oncology.
This approach is already offered to women who undergo lumpectomy for breast cancer, researchers said in background notes.
“These results give us the data to safely change practice,” lead researcher Dr. Matthew Poppe, a radiation oncologist at the University of Utah, said in a news release.
“Patients undergoing mastectomy and reconstruction already face a challenging medical journey,” Poppe said. “Having the evidence to allow women to confidently shorten their radiation treatment from five weeks down to three will save patients time, reduce their financial stress, and let them get back to their daily lives sooner — all without increasing complications, lowering their chances of cure, or sacrificing cosmetic results.”
For years, doctors have used a shorter radiation schedule to treat breast cancer patients who undergo a lumpectomy that removes the tumor while preserving the breast.
With this approach, women receive slightly higher daily doses of radiation at each treatment, reducing the therapy time by nearly half.
However, the shorter-course radiation has not been offered for women opting for full breast reconstruction following a mastectomy, researchers said. Doctors worried that higher radiation doses could affect reconstruction.
For the trial, researchers recruited 828 patients at 209 hospitals across the United States and Canada.
Half randomly received the standard radiation course, while the other half received the shorter schedule. The standard regimen was 25 visits over five to six weeks; the shorter was 16 treatments for three to four weeks.
Results showed that complication rates for breast reconstruction were similar between the two groups — about 12 percent for those on the short schedule and 10 percent for those who got regular radiation therapy.
Both approaches were also similarly successful in remission. Recurrence rates were 1.5 percent for the short schedule and 2.2 percent for the standard schedule.
The clinical trial “provides the clearest picture to date on how shorter radiation therapy schedules interact with modern breast reconstruction techniques,” Poppe said. “It gives radiation oncologists, breast surgeons and plastic surgeons the reliable information they need to help patients make the most informed choices for their care.”
RELATED: The Importance of Breast Cancer Clinical Trials
Shorter radiation schedules deliver a higher dose per session over fewer weeks (typically three to four weeks, or even five days for ultra-hypofractioned protocols) than the traditional five- to seven-week daily regimen.
A shorter schedule may provide several benefits, including:
Clinical trials like this one help researchers identify ways to make treatments more effective and more convenient for patients.
Although the study didn’t specifically focus on Black patients, its findings may be particularly meaningful for communities disproportionately affected by breast cancer disparities. Research has shown that Black women often face greater barriers to timely cancer treatments, including transportation issues, financial challenges, and limited access to specialty care.
A shorter radiation treatment schedule could potentially make it easier for some patients to complete recommended care.
RELATED: Understanding Breast Cancer Clinical Trials for Black Women
Clinical trials help improve treatments and quality of life. As more treatment approaches emerge, diverse participation in clinical trials remains critical. Including more Black patients in breast cancer clinical trials can help researchers understand how treatments perform across populations and supports more equitable cancer care.
To explore open trials or learn more about what participation can entail, visit BlackDoctor’s Clinical Trials Resource Center.
More information
The American Cancer Society has more on radiation for breast cancer.
SOURCE: Alliance for Clinical Trials in Oncology, news release, Oct. 21, 2026
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
